Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Trial Profile

A Phase 2b Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avacincaptad pegol (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors IVERIC bio
  • Most Recent Events

    • 04 Nov 2019 According to an IVERIC bio media release, the trial results will be presented in a Zimura R&D Symposium for Investors on Wednesday, November 20, 2019.
    • 28 Oct 2019 Results presented in an IVERIC bio media release
    • 28 Oct 2019 Primary endpoint has been met. (Change in geographic atrophy (GA)), according to an IVERIC bio media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top